The manufacturers of Tysabri, Biogen Idec Inc. and Elan Corp. plc warned about reports of liver toxicity in patients treated with the drug. The companies sent a letter to healthcare professionals (dear doctor letter), notifying them about the potential risks. This warning came just a couple of weeks after a letter in the New England Journal of Medicine cautioned doctors about two aggressive cases of malignant melanoma that occurred shortly after Tysabri was administered.
Tysabri is the brand name for natalizumab, a monoclonal antibody that is approved for the treatment of Multiple Sclerosis (MS) and Crohn’s disease. Tysabri was first approved by the FDA in November 2004, but was removed from the market just three months later after several patients were diagnosed with a rare, often fatal opportunistic brain infection called progressive multifocal leukoencephalopathy (PML). The FDA allowed Tysabri back on the market in June 2006 for the treatment of Multiple Sclerosis with revised warnings and strict requirements for close monitoring of patients receiving the drug. Earlier this year, the FDA approved Tysabri for the treatment of Crohn’s disease.
The legal professionals at Mark & Associates, P.C. have a track record of both past and present litigation against Biogen Idec and Elan on behalf of Tysabri victims. The firm currently represents the family of a patient who died from an opportunistic infection after receiving Tysabri. In 2006, Jason Mark, the managing partner of Mark & Associates, P.C., represented the family of a woman who died from PML following Tysabri treatment.
Legal Help for Tysabri Patients
If you or a loved one has been diagnosed with severe cases of liver damage or melanoma after taking Tysabri, you may have valuable legal rights. Mark & Associates, P.C. offers Tysabri patients and their families free legal consultations. You can request a free legal consultation by completing the inquiry form on this page, or by calling 1-866-50-RIGHTS (1-866-507-4448).